Ole Schwander/iStock via Getty Images Ginkgo Bioworks ( NYSE: DNA ) fell to a historic low in the morning hours Tuesday after Ark ETFs, run by notable fund manager Cathie Wood, sold approximately 41.6M of shares of the cell programming platform company. About 62.
9M shares of Ginkgo ( DNA ) have changed hands so far, compared to the 65-day average of ~44.6M as the stock plunged to the lowest level since its public debut, made in combination with a special purpose acquisition company in 2021. The selloff came after ARK ETFs ARK Innovation ETF ( ARKK ) and ARK Genomic Revolution ( ARKG ) sold ~33.
6M and ~8.0M shares of DNA, respectively, as part of their trading activity on Monday. Cathie Wood-run ETFs have staunchly backed the Boston, Massachusetts, firm in the past, buying millions of its shares even in the face of a scathing short report by Scorpion Capital weeks after its trading debut.
More on Ginkgo Bioworks Holdings Ginkgo Bioworks: Massive Revenue Warning Ginkgo Bioworks: Broken Narrative Ginkgo Bioworks Holdings, Inc. (DNA) Q1 2024 Earnings Call Transcript Ginkgo slips as BTIG cuts to Sell on strategic shift Ginkgo Bioworks receives NYSE listing standard notice.
